PURPOSE: To detect regional metabolic differences in amyotrophic lateral sclerosis (ALS) with whole-brain echo-planar spectroscopic imaging. MATERIALS AND METHODS: Sixteen patients with ALS (nine men, seven women; mean age, 56.6 years), five persons suspected of having ALS (four men, one woman; mean age, 62.6 years), and 10 healthy control subjects (five men, five women; mean age, 56.1 years) underwent echo-planar spectroscopic imaging after providing informed consent. The study was approved by the institutional review board and complied with HIPAA. Data were analyzed with the Metabolic Imaging and Data Analysis System software, and processed metabolite maps were coregistered and normalized to a standard brain template. Metabolite maps of creatine (Cr), choline (Cho), and N-acetylaspartate (NAA) were segmented into 81 regions with Automated Anatomical Labeling software to measure metabolic changes throughout the brains of patients with ALS. Statistical analysis involved an unpaired, uncorrected, two-sided Student t test. RESULTS: The NAA/Cho ratio across six regions was significantly lower by a mean of 23% (P ≤ .01) in patients with ALS than in control subjects. These regions included the caudate, lingual gyrus, supramarginal gyrus, and right and left superior and right inferior occipital lobes. The NAA/Cr ratio was significantly lower (P ≤ .01) in eight regions in the patient group, by a mean of 16%. These included the caudate, cuneus, frontal inferior operculum, Heschl gyrus, precentral gyrus, rolandic operculum, and superior and inferior occipital lobes. The Cho/Cr ratio did not significantly differ in any region between patient and control groups. CONCLUSION: Whole-brain echo-planar spectroscopic imaging permits detection of regional metabolic abnormalities in ALS, including not only the motor cortex but also several other regions implicated in ALS pathophysiologic findings.
PURPOSE: To detect regional metabolic differences in amyotrophic lateral sclerosis (ALS) with whole-brain echo-planar spectroscopic imaging. MATERIALS AND METHODS: Sixteen patients with ALS (nine men, seven women; mean age, 56.6 years), five persons suspected of having ALS (four men, one woman; mean age, 62.6 years), and 10 healthy control subjects (five men, five women; mean age, 56.1 years) underwent echo-planar spectroscopic imaging after providing informed consent. The study was approved by the institutional review board and complied with HIPAA. Data were analyzed with the Metabolic Imaging and Data Analysis System software, and processed metabolite maps were coregistered and normalized to a standard brain template. Metabolite maps of creatine (Cr), choline (Cho), and N-acetylaspartate (NAA) were segmented into 81 regions with Automated Anatomical Labeling software to measure metabolic changes throughout the brains of patients with ALS. Statistical analysis involved an unpaired, uncorrected, two-sided Student t test. RESULTS: The NAA/Cho ratio across six regions was significantly lower by a mean of 23% (P ≤ .01) in patients with ALS than in control subjects. These regions included the caudate, lingual gyrus, supramarginal gyrus, and right and left superior and right inferior occipital lobes. The NAA/Cr ratio was significantly lower (P ≤ .01) in eight regions in the patient group, by a mean of 16%. These included the caudate, cuneus, frontal inferior operculum, Heschl gyrus, precentral gyrus, rolandic operculum, and superior and inferior occipital lobes. The Cho/Cr ratio did not significantly differ in any region between patient and control groups. CONCLUSION: Whole-brain echo-planar spectroscopic imaging permits detection of regional metabolic abnormalities in ALS, including not only the motor cortex but also several other regions implicated in ALS pathophysiologic findings.
Authors: N Tzourio-Mazoyer; B Landeau; D Papathanassiou; F Crivello; O Etard; N Delcroix; B Mazoyer; M Joliot Journal: Neuroimage Date: 2002-01 Impact factor: 6.556
Authors: Miriam Sach; Gerhard Winkler; Volkmar Glauche; Joachim Liepert; Bernhard Heimbach; Martin A Koch; Christian Büchel; Cornelius Weiller Journal: Brain Date: 2003-11-07 Impact factor: 13.501
Authors: Varan Govind; Khema R Sharma; Andrew A Maudsley; Kristopher L Arheart; Gaurav Saigal; Sulaiman Sheriff Journal: PLoS One Date: 2012-04-23 Impact factor: 3.240
Authors: Juan R Bustillo; Thomas Jones; Hongji Chen; Nicholas Lemke; Christopher Abbott; Clifford Qualls; Shannon Stromberg; Jose Canive; Charles Gasparovic Journal: Schizophr Bull Date: 2017-05-01 Impact factor: 9.306
Authors: Maryse Feron; Annabelle Couillandre; Eya Mseddi; Nicolas Termoz; Malek Abidi; Eric Bardinet; Daniel Delgadillo; Timothée Lenglet; Giorgia Querin; Marie-Laure Welter; Nadine Le Forestier; François Salachas; Gaelle Bruneteau; Maria Del Mar Amador; Rabab Debs; Lucette Lacomblez; Vincent Meininger; Mélanie Pélégrini-Issac; Peter Bede; Pierre-François Pradat; Giovanni de Marco Journal: J Neurol Date: 2018-07-11 Impact factor: 4.849
Authors: Sabah Nisar; Ajaz A Bhat; Tariq Masoodi; Sheema Hashem; Sabah Akhtar; Tayyiba Akbar Ali; Sara Amjad; Sanjeev Chawla; Puneet Bagga; Michael P Frenneaux; Ravinder Reddy; Khalid Fakhro; Mohammad Haris Journal: Mol Psychiatry Date: 2022-03-16 Impact factor: 13.437
Authors: G Grolez; C Moreau; V Danel-Brunaud; C Delmaire; R Lopes; P F Pradat; M M El Mendili; L Defebvre; D Devos Journal: BMC Neurol Date: 2016-08-27 Impact factor: 2.474